Skip to content ↓

Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB

STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.

Published: August 1, 2022

Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.